These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19877987)

  • 21. Aptensio XR--another long-acting methylphenidate.
    Med Lett Drugs Ther; 2015 Jul; 57(1473):101-3. PubMed ID: 26204039
    [No Abstract]   [Full Text] [Related]  

  • 22. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler.
    Lipkin PH; Butz AM; Cozen MA
    J Child Adolesc Psychopharmacol; 2003; 13(1):103-6. PubMed ID: 12804131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial.
    Gerwe M; Stollhoff K; Mossakowski J; Kuehle HJ; Goertz U; Schaefer C; Bogdanow M; Heger S
    Atten Defic Hyperact Disord; 2009 Dec; 1(2):175-86. PubMed ID: 21432582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase in Menstrual Cycle Length Induced by Extended-Release Methylphenidate in an Adolescent with Attention-Deficit/Hyperactivity Disorder.
    Mutlu C; Bahalı K; Gunes H; Adaletli H
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):860-861. PubMed ID: 26397126
    [No Abstract]   [Full Text] [Related]  

  • 28. QuilliChew ER--extended-release chewable methylphenidate tablets.
    Med Lett Drugs Ther; 2016 May; 58(1495):68-9. PubMed ID: 27192619
    [No Abstract]   [Full Text] [Related]  

  • 29. OROS-Methylphenidate-Induced Raynaud's Phenomenon: A Dose-Related Side Effect.
    Bayram Ö; Hergüner S
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):521-2. PubMed ID: 26222712
    [No Abstract]   [Full Text] [Related]  

  • 30. [How safe are ADHD drugs?].
    Schwarz R; Muskalla B
    Kinderkrankenschwester; 2005 Oct; 24(10):437. PubMed ID: 16262203
    [No Abstract]   [Full Text] [Related]  

  • 31. Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
    Hollis CP; Thompson A
    Pediatr Neurol; 2007 Oct; 37(4):287-8. PubMed ID: 17903675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trichotillomania in Attention-Deficit/Hyperactivity Disorder Under Methylphenidate Treatment.
    Kara T; Akaltun İ
    J Clin Psychopharmacol; 2017 Aug; 37(4):484. PubMed ID: 28492426
    [No Abstract]   [Full Text] [Related]  

  • 34. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study.
    Marchant BK; Reimherr FW; Halls C; Williams ED; Strong RE
    Ann Clin Psychiatry; 2010 Aug; 22(3):196-204. PubMed ID: 20680193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?
    Mott TF; Leach L; Johnson L
    J Fam Pract; 2004 Aug; 53(8):659-61. PubMed ID: 15298843
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacological management of treatment-induced insomnia in ADHD.
    Kratochvil CJ; Lake M; Pliszka SR; Walkup JT
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):499-501. PubMed ID: 15843773
    [No Abstract]   [Full Text] [Related]  

  • 37. Reversible Alopecia Secondary to OROS Methylphenidate.
    Núñez-Garces M; Sánchez-Gayango A; Romero-Pérez C
    Rev Colomb Psiquiatr (Engl Ed); 2020; 49(3):208-210. PubMed ID: 32888666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful desensitization of methylphenidate-induced rash.
    Confino-Cohen R; Goldberg A
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):703-5. PubMed ID: 16190802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasal Bleeding Probably Associated with Methylphenidate.
    Avcil S
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):924-925. PubMed ID: 29131668
    [No Abstract]   [Full Text] [Related]  

  • 40. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.
    Biederman J; Mick E; Fried R; Wilner N; Spencer TJ; Faraone SV
    Eur Neuropsychopharmacol; 2011 Jul; 21(7):508-15. PubMed ID: 21303732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.